These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 30789853)
1. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? Bischoff J; Boesecke C; Ingiliz P; Berger F; Simon KG; Lutz T; Schewe CK; Schulze Zur Wiesch J; Hueppe D; Christensen S; Mauss S; Baumgarten A; Rockstroh JK; J Clin Gastroenterol; 2020 Feb; 54(2):192-199. PubMed ID: 30789853 [TBL] [Abstract][Full Text] [Related]
2. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547 [TBL] [Abstract][Full Text] [Related]
3. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337 [TBL] [Abstract][Full Text] [Related]
4. Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study). Monin MB; Ingiliz P; Lutz T; Scholten S; Cordes C; Martínez-Rebollar M; Spinner CD; Nelson M; Rausch M; Bhagani S; Peters L; Reiberger T; Mauss S; Rockstroh JK; Boesecke C; Clin Infect Dis; 2023 Feb; 76(3):e607-e612. PubMed ID: 36004410 [TBL] [Abstract][Full Text] [Related]
5. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies. Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M; Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708 [TBL] [Abstract][Full Text] [Related]
6. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018. Cotte L; Hocqueloux L; Lefebvre M; Pradat P; Bani-Sadr F; Huleux T; Poizot-Martin I; Pugliese P; Rey D; Cabié A; Clin Infect Dis; 2021 Nov; 73(9):e3266-e3274. PubMed ID: 33400777 [TBL] [Abstract][Full Text] [Related]
8. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV; Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984 [TBL] [Abstract][Full Text] [Related]
9. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands. Isfordink CJ; Smit C; Boyd A; de Regt MJA; Rijnders BJA; van Crevel R; Ackens RP; Reiss P; Arends JE; van der Valk M; AIDS; 2022 May; 36(6):773-783. PubMed ID: 34999607 [TBL] [Abstract][Full Text] [Related]
10. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study. Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685 [TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952 [TBL] [Abstract][Full Text] [Related]
12. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era. Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ; Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Clinical Manifestations of Acute Hepatitis C Infection in People Living with HIV. O'Shea J; Oliver N; Cartwright EJ AIDS Patient Care STDS; 2022 May; 36(5):172-177. PubMed ID: 35507325 [TBL] [Abstract][Full Text] [Related]
14. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735 [TBL] [Abstract][Full Text] [Related]
15. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456 [TBL] [Abstract][Full Text] [Related]
17. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063 [TBL] [Abstract][Full Text] [Related]
18. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands. Boerekamps A; Newsum AM; Smit C; Arends JE; Richter C; Reiss P; Rijnders BJA; Brinkman K; van der Valk M; Clin Infect Dis; 2018 Apr; 66(9):1352-1359. PubMed ID: 29186365 [TBL] [Abstract][Full Text] [Related]
19. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection. Yin X; Kong L; Du P; Jung J AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640 [TBL] [Abstract][Full Text] [Related]
20. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan. Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]